Table 3.
Outcome Response Rates for SRL Medications
| Outcome | All Studies (n = 90) | LAN ATG (n = 16) | OCT LAR (n = 34) | P Value |
|---|---|---|---|---|
| GH response (%) | ||||
| Mean (SD) | 56 (19.7) | 64 (17.5) | 58 (16.2) | .30 |
| Median (IQR) | 55 (44–69) | 59 (49–78) | 60 (45–70) | |
| Missing (%) | 5 (5.6) | 1 (6.3) | 0 (0) | |
| IGF-1 normalization (%) | ||||
| Mean (SD) | 55 (17.3) | 61 (14.8) | 55 (18.4) | .23 |
| Median (IQR) | 54 (42.5–65) | 56 (51–64) | 61 (36–66) | |
| Missing (%) | 2 (2.2) | 0 (0) | 0 (0) |
Abbreviations: IQR, interquartile range; LAN ATG, lanreotide autogel/depot; OCT LAR, octreotide long-acting repeatable.